Iridex Issues Recall of TruFocus LIO Premiere Laser Indirect Ophthalmoscope

March 2, 2018: By Jon Swedien

Iridex has initiated a voluntary recall of its TruFocus LIO Premiere laser indirect ophthalmoscope.

The Mountain View, California, company announced the recall Feb. 23, after receiving reports of three adverse events during procedures using the laser accessory. Patients experienced permanent damage to the eye, including focal cataracts and iris burns, Iridex said.

The LIO is a head-mounted indirect ophthalmoscope that connects to an Iridex laser console and is used to view and perform laser treatments.

Customers should not use TruFocus LIO Premieres with part numbers 87300, 87301, 87302, 87303, and 87304, Iridex said. The company said there are 104 units at customer sites worldwide.

Iridex said it is notifying its distributors and customers via FedEx and is arranging for return of all recalled products. The company said it has notified the US FDA of the action.

Recalled products were manufactured from May 26, 2017, to Nov. 6, 2017, and distributed from June 5, 2017, to Jan. 29, 2018, the company said.

After the recall, Iridex revised its preliminary financial results for Q4-2017 and the full year.

Iridex’ total revenues for Q4-2017 are now expected to be between $10.2 million to $10.3 million. Iridex had expected the quarter’s total revenues to range from $11 million to $11.1 million.

The company’s total revenues for 2017 are expected to range between $41.5 million and $41.6 million after the recall. Previously, the company expected its 2017 revenues to range between $42.3 million and $42.4 million.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023